Enger C, Bennett D, Dawson KL, Aivado MA, Theodore D, McAfee AT

Idioma: Ingles.
Referencias bibliográficas: 7
Paginas: 188-195
Archivo PDF: 66.37 Kb.

RESUMEN

Sin resumen.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Rodeghiero F, Stasi R, Gernsheimer T, Michel M, Provan D, Arnold DM, Bussell JB, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: Report from an international working group. Blood 2009; 113(11): 2386-93.

2. Cines DB, Blanchette VS. Immune thrombocytopenic purpura. N Engl J Med 2002; 346(13): 995-1008.

3. Limdi JK, Hyde GM. Evaluation of abnormal liver function tests. Postgrad Med J 2003; 79(932): 307-12.

4. Temple R. HY’s law: Predicting serious hepatotoxicity. Pharmacoepidemiol Drug Saf 2006; 15(4): 241-3.

5. US Department of Health and Human Services, FDA. Guidance for Industry: Drug Induced Liver Injury: Premarketing Clinical Evaluation. FDA 2007.

6. Epstein M. Guidelines for good pharmacoepidemiology practices (GPP). Pharmacoepidemiol Drug Saf 2008; 17(2): 2008.

7. Makar GA, Weiner MG, Kimmel SE, Bennett D, Burke A, Yang YX, Han X, et al. Incidence and prevalence of abnormal liver associated enzymes in patients with atrial fibrillation in a routine clinical care population. Pharmacoepidemiol Drug Saf 2008; 17(1):43-51.